» Articles » PMID: 25944164

The Role of Osteopontin Expression in Melanoma Progression

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2015 May 7
PMID 25944164
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

It was shown that osteopontin (OPN), a glycophosphoprotein, plays divergent roles in cancer progression. In addition to multiple intra- and extracellular functions, it facilitates migration of tumour cells, has crucial role in cell adhesion and is associated with increased metastasis formation. In previous studies, we performed global gene expression profiling on a series of primary melanoma samples and found that OPN was significantly overexpressed in ulcerated melanomas. The major purpose of this study was to define OPN expression in primary melanomas with differing biological behaviours. OPN mRNA expression was analysed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in primary melanoma tissues. Immunohistochemistry was performed using a tissue microarray. Cox regression tests were used for survival analysis. Greater than 50 % of the tissues exhibited high protein expression that was significantly associated with tumour thickness and metastasis. OPN mRNA expression was significantly increased in thicker melanomas and lesions with an ulcerated surface. Increased expression was primarily detected in advanced-stage tumours. A multivariate Cox regression analysis revealed that high OPN expression, tumour thickness and metastasis were significantly associated with reduced relapse-free survival. In summary, high OPN mRNA and protein expression were associated with a less favourable clinical outcome of primary melanoma patients. We determined that OPN is a significant predictive factor for the survival of primary melanoma patients. Based on our and others data, the high expression of OPN may have a crucial stimulatory role in tumour progression and metastasis formation, which, thus, have been proposed as potential targets for cancer diagnosis and therapy.

Citing Articles

Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy.

Levati L, Tabolacci C, Facchiano A, Facchiano F, Alvino E, Antonini Cappellini G J Exp Clin Cancer Res. 2024; 43(1):226.

PMID: 39143551 PMC: 11325673. DOI: 10.1186/s13046-024-03151-3.


Combining Biomarkers for the Diagnosis of Metastatic Melanoma.

Varvolgyi T, Janka E, Szasz I, Koroknai V, Toka-Farkas T, Szabo I J Clin Med. 2024; 13(1).

PMID: 38202181 PMC: 10779676. DOI: 10.3390/jcm13010174.


Thrombin Cleavage of Osteopontin and the Host Anti-Tumor Immune Response.

Leung L, Myles T, Morser J Cancers (Basel). 2023; 15(13).

PMID: 37444590 PMC: 10340489. DOI: 10.3390/cancers15133480.


Increased Circulating Osteopontin Levels Promote Primary Tumour Growth, but Do Not Induce Metastasis in Melanoma.

Saup R, Nair N, Shen J, Schmaus A, Thiele W, Garvalov B Biomedicines. 2023; 11(4).

PMID: 37189656 PMC: 10135562. DOI: 10.3390/biomedicines11041038.


Gene Expression Patterns of Osteopontin Isoforms and Integrins in Malignant Melanoma.

Jambor K, Koroknai V, Kiss T, Szasz I, Piko P, Balazs M Pathol Oncol Res. 2022; 28:1610608.

PMID: 36091936 PMC: 9448871. DOI: 10.3389/pore.2022.1610608.


References
1.
Cao D, Li Z, Jiang X, Lum Y, Khin E, Lee N . Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 2012; 18(30):3923-30. PMC: 3419986. DOI: 10.3748/wjg.v18.i30.3923. View

2.
Denhardt D . Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005; 124(5):xvi-xviii. DOI: 10.1111/j.0022-202X.2005.23708.x. View

3.
Maier T, Laubender R, Sturm R, Klingenstein A, Korting H, Ruzicka T . Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J Eur Acad Dermatol Venereol. 2011; 26(9):1084-91. DOI: 10.1111/j.1468-3083.2011.04210.x. View

4.
Das R, Philip S, Mahabeleshwar G, Bulbule A, Kundu G . Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life. 2005; 57(6):441-7. DOI: 10.1080/15216540500159424. View

5.
Rangaswami H, Bulbule A, Kundu G . Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16(2):79-87. DOI: 10.1016/j.tcb.2005.12.005. View